ART Advanced Research Technologies Inc. Translational Imaging Platform Showcased at the World Molecular Imaging Congress in Montreal, Canada

MONTREAL, CANADA--(Marketwire - September 21, 2009) - ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that current research relating to its molecular imaging products will be presented at poster sessions at the World Molecular Imaging Congress (WMIC), being held at the Palais des congres in Montreal, Canada, from September 23 to 26, 2009. ART is also displaying its Optix®, SoftScan® and Fenestra® product offering as an exhibitor at the event (booth #301), in the Exhibit Hall of the Palais des congres.

Prior to the start of the meeting - on Tuesday, September 22 - ART will hold a ART User Forum, where Optix users from major pharmaceutical companies and research institutes will present their work, and provide a hands-on opportunity for potential clients to learn about new developments and applications available for the Optix system, as well as the capability for translational research using the SoftScan® breast imaging device. Both products are based on the proprietary time domain technology developed by ART, which allows for more accurate recovery of depth and concentration than other optical systems.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART’s shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2008, available on SEDAR (www.sedar.com).